Protalix BioTherapeutics, Inc.

PLX NYSE CIK: 0001006281

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601
Mailing Address 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601
Phone 201-696-9345
Fiscal Year End 1231
EIN 650643773

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 30, 2026 View on SEC
8-K Current report of material events March 18, 2026 View on SEC
10-K Annual financial report March 18, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 4, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC
8-K Current report of material events January 5, 2026 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report November 19, 2025 View on SEC

Annual Reports

10-K March 18, 2026
  • Protalix utilizes a unique plant cell-based expression system for developing therapeutic proteins.
  • Elfabrio® (pegunigalsidase alfa-iwxj), their flagship product, is approved for adults with Fabry disease.
View Analysis

Insider Trading

BUY 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.